16 July 2021
A Powerful Workflow to Access Cancer Gene Expression Signatures
In additional to DNA sequencing, RNA sequencing can provide researchers and clinicians with additional insights into tumor tissues. The technology offers the opportunity to explore the gene expression profiles and the states of tumor cells in real time.
25 June 2021
Founded in 1961, the Antoine Lacassagne Center is one of the 18 French Cancer Centers of the Unicancer network. It fulfills missions of care, research and teaching in oncology. The Antoine Lacassagne Center treats all types of cancer and receives more than 6,400 patients (…) »
16 June 2021
Following its acquisition by OncoDNA, IntegraGen has been given a brand new look and is ready to take on new projects in the fields of cancer and genetic diseases.
Since the successful takeover in November 2020, IntegraGen has been working hand in hand with OncoDNA (…) »
19 May 2021
Integrated genomic analysis identifies driver genes and cisplatin-resistant progenitor phenotype in pediatric liver cancer
IntegraGen is delighted to share this new publication on tumor plasticity and cisplatin resistance in pediatric liver cancers. Sequencing services (WES, RNA-seq, snRNA-seq, RRBS) and expertise support, particularly for single nuclei RNA-seq experiment, (…) »
15 March 2021
Uropathogenic E.coli induces DNA damage in the bladder
As provider of the whole genome sequencing, IntegraGen is proud of sharing this new publication.
Urinary tract infections (UTIs) are caused by an uropathogenic strain of Escherichia coli that produce colibactin, a bacterial genotoxin.
In the study (…) »
03 March 2021
Myogenesis modelled by human pluripotent stem cells: a multi-omic study of Duchenne myopathy early onset
As provider of the bulk and single-cell RNA-seq libraries and sequencing, IntegraGen is proud of sharing this new publication.
Duchenne Muscular Dystrophy (DMD) is a rare disease characterized by early muscular damages. The (…) »
09 October 2020
LP-WGS analysis of liquid biopsies (ctDNA) for oncology applications Background
Analysis of circulating tumor DNA (ctDNA) offers great opportunities for cancer research and patient care. There are multiple applications and benefits associated with studying ctDNA including the ability to identify tumor heterogeneity and the detection of somatic mutations unidentified following (…) »
10 June 2020
Our latest release: MERCURY™ v3.0
We are excited to provide you with important information regarding the release of a new version (v3.0) of MERCURY™. This updated version of MERCURY has a number of changes and improvements designed to enhance data analysis capabilities and the user experience.
MERCURY v3.0 has (…) »
13 April 2020
IntegraGen announces the company’s MERCURY™ cloud-based analytical software tool has achieved Conformité Européenne (CE) marking. This registration enhances the ability for IntegraGen sell MERCURY throughout the European Union (EU). MERCURY is utilized by researchers and clinicians to assist with the analysis of sequencing data derived from small (…) »
31 March 2020
IntegraGen is following the French Government’s recommendations and precautionary measures for COVID-19. As an essential supplier of genomic research services, we are committed to meeting the needs of our customers while also making every effort to protect the health and well-being of our employees and their families.
We have undertaken (…) »